Skip to main content

Verastem, Inc.

VSTM
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001526119

In the last 90 days, Verastem, Inc. insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $363.5M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Verastem, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $7.99K in total
Insiders trading
2
Net value
−$7.99K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Verastem, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Verastem, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Calkins DanielChief Financial Officer118,014Sep 23, 20266
Paterson DanPresident and CEO589,940Aug 5, 202613
Bailey Michael PDirector108,000May 27, 20261
Rowinsky Eric KDirector52,666May 26, 20261
Johnson JohnDirector52,666May 26, 20261
Stuglik Brian MDirector137,147May 26, 20262
Kapur AnilDirector52,666May 26, 20261
Robertson MichelleDirector52,666May 26, 20261
Bunn Paul A.Director44,333May 26, 20263
Tollefson Karin AnnaDirector52,666May 26, 20261
Kauffman MichaelPresident of Development8,666Jan 8, 20262
Gagnon Robert E.Director41,678Dec 18, 20251
Ros MatthewChief Operating Officer50,000Apr 3, 20250
Solomon Lesley KimDirector–Dec 20, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 22, 2022 (view filing)Jun 211 dayPaterson DanPresident and COOSSale−2.70K$1.14−$3.08K−0.6%485.2K after
Jun 22, 2022 (view filing)Jun 211 dayStuglik Brian MChief Executive OfficerSSale−3.36K$1.14−$3.83K−0.3%1.16M after
Jun 22, 2022 (view filing)Jun 211 dayGagnon Robert E.Chief Financial OfficerSSale−1.35K$1.14−$1.54K−0.2%589.9K after
May 17, 2022 (view filing)May 161 dayPaterson DanPresident and COOSSale−4.99K$1.03−$5.14K−1.0%487.9K after
May 17, 2022 (view filing)May 161 dayStuglik Brian MChief Executive OfficerSSale−13.8K$1.03−$14.2K−1.2%1.16M after
May 17, 2022 (view filing)May 161 dayGagnon Robert E.Chief Financial OfficerSSale−16.6K$1.03−$17.1K−2.7%591.3K after
May 4, 2022 (view filing)May 22 daysStuglik Brian MChief Executive OfficerSSale−5.86K$1.41−$8.26K−0.5%1.13M after
Mar 23, 2022 (view filing)Mar 212 daysPaterson DanPresident and COOSSale−2.82K$1.27−$3.58K−0.6%477.9K after
Mar 23, 2022 (view filing)Mar 212 daysStuglik Brian MChief Executive OfficerSSale−3.51K$1.27−$4.45K−0.3%1.13M after
Mar 23, 2022 (view filing)Mar 212 daysGagnon Robert E.Chief Financial OfficerSSale−1.41K$1.27−$1.79K−0.3%557.9K after
Feb 2, 2022 (view filing)Jan 312 daysStuglik Brian MChief Executive OfficerSSale−5.70K$1.48−$8.43K−0.5%1.14M after
Jan 5, 2022 (view filing)Jan 32 daysStuglik Brian MChief Executive OfficerSSale−26.0K$2.05−$53.4K−2.2%1.14M after
Jan 5, 2022 (view filing)Jan 32 daysGagnon Robert E.Chief Financial OfficerSSale−19.6K$2.05−$40.2K−3.4%559.3K after
Jan 5, 2022 (view filing)Jan 32 daysPaterson DanPresident and COOSSale−23.5K$2.05−$48.2K−4.7%480.8K after
Dec 22, 2021 (view filing)Dec 202 daysStuglik Brian MChief Executive OfficerSSale−13.7K$2.27−$31.1K−1.2%1.17M after
Dec 22, 2021 (view filing)Dec 202 daysPaterson DanPresident and COOSSale−11.0K$2.27−$25.0K−2.1%504.3K after
Dec 22, 2021 (view filing)Dec 202 daysGagnon Robert E.Chief Financial OfficerSSale−5.50K$2.27−$12.5K−0.9%578.9K after